Citations

Mayo Clinic

Showing 10 of 108602 citations.

Therapeutic plasma exchange causing (not curing) hemolysis
Graham, Brendan C. , Burgstaler, Edwin A. , Winters, Jeffrey L. , Winters, Jeffrey L

Journal of Clinical Apheresis | October 30, 2017 | Volume: 33 | Issue: 3 | Pages: 393-395

10.1002/jca.21596 | PMID 29083046 Get It

The contribution of pain in determining the health status of cancer patients with bone metastases: A secondary analysis of data from three Phase III registration trials
Mendoza, Tito R. , Dueck, Amylou C. , Ma, Haijun , Zhang, J., Qian, Yi , Cleeland, Charles S. , Dueck, A. C. , Mendoza, Tito , Shi, Qiuling

European Journal of Pain | October 30, 2017 | Volume: 22 | Issue: 3 | Pages: 565-571

10.1002/ejp.1139 | PMID 29082574 Get It

AbstractBackgroundWe aimed to provide a simple, descriptive health‐status profile for cancer patients with bone metastases, based on the EuroQol EQ‐5D, a tool commonly used to measure health utility scores, and to evaluate its association with the Brief Pain Inventory (BPI), a legacy pain‐assessment tool. Although pain is one of five health‐status dimensions measured by the EQ‐5D, our understanding of how pain relates to the other EQ‐5D dimensions is limited.MethodsWe derived data from 5500 patients with bone metastases who completed the EQ‐5D and BPI. Regression analyses examined how BPI severity and interference scores correlated with EQ‐5D utility scores and how BPI items associated with EQ‐5D items, for the entire sample and by disease‐type subgroup.ResultsRegardless of cancer site, the percentage of patients reporting moderate/severe problems in each of the five EQ‐5D dimensions were pain/discomfort, 78%; usual activities, 58%; mobility, 55%; anxiety/depression, 57%; and self‐care, 26%. BPI pain interference explained more of the variability in the EQ‐5D utility scores than did pain severity (R2 = 41% vs. 34%). BPI worst pain, average pain, pain now, interference with general activity, and interference with work significantly predicted EQ‐5D pain/discomfort, with odds ratio estimates <1.ConclusionsPain/discomfort was the worst‐rated dimension of the EQ‐5D in this population, but the relationship of this item to BPI pain severity was modest, suggesting that the single pain item of the EQ‐5D may be of limited utility in studies for which pain is an endpoint.SignificanceHealth‐status dimensions include more than pain. We examine the contribution of pain severity and pain‐related functional interference in determining the health status of cancer patients with bone metastases. The pain dimension from a health‐status measure may be an inadequate metric in clinical trials/clinical practice when pain is an important outcome.
Addressing Pediatric Obesity in Clinic
Ahanogbe, Isabella, Thurston, McKennan J., White, Richard O. , Roche‐Green, Alva, Pujalte, George G.A. , Roche-Green, Alva

Global Pediatric Health | October 30, 2017 | Volume: 4 | Issue: No issue available | Pages: No page available

10.1177/2333794x17736971 | PMID 29119130 Get It

There is an epidemic of pediatric obesity in the United States. In most cases, there is an excess in the amount of calories consumed, compared with the amount of calories expended. Numerous body systems are affected by pediatric obesity, with complications varying between boys and girls. Behavioral, genetic, and environmental factors affect the ability of children to avoid becoming obese. Primary care physicians should screen for obesity in children as much as possible. Associated risk factors for obesity should be uncovered. Methods of preventing obesity should be discussed routinely with children and their families. Healthy dietary habits are key, and so are family-oriented interventions, such as eating together at dinnertime. One hour of moderate to vigorous activity daily is recommended for children and adolescents. While pediatric bariatric surgery is an option, there are also numerous nonpharmacological and pharmacological measures available as management for pediatric obesity. Family-based approaches, such as reducing screen time, have been very successful. Non–weight-bearing exercises also help children and adolescents expend calories without causing injury to themselves. Family availability, activity preference, and developmental levels should all be considerations when managing pediatric obesity. Motivational interviewing may also be helpful, especially when customized for each specific patient and family. Clinicians will play an increasing role in terms of identifying, treating, and preventing pediatric obesity; measures that can be done in the clinic should be considered more and more.
Cognitive impairment in progressive supranuclear palsy is associated with tau burden
Koga, Shunsuke , Parks, Adam , Kasanuki, Koji , Josephs, Keith A. , Ahlskog, J. Eric , Uitti, Ryan J. , Graff‐Radford, Neill R. , Gerpen, Jay A. van, Rademakers, Rosa , Baker, Matthew C, Van Gerpen, Jay A, Koga, Shunsuke , Sánchez-Contreras, Mónica , Baker, Matthew , Wszołek, Zbigniew K. , Dickson, Dennis W.

Movement Disorders | October 30, 2017 | Volume: 32 | Issue: 12 | Pages: 1772-1779

10.1002/mds.27198 | PMID 29082658 Get It

Abstract Background Cognitive impairment is one of the core features of progressive supranuclear palsy. This study aimed to clarify the profile of cognitive impairment and its underlying pathology in progressive supranuclear palsy. Methods We retrospectively reviewed medical records to evaluate the pattern and severity of cognitive impairment in 121 autopsy‐confirmed progressive supranuclear palsy patients. A subset of 37 patients underwent neuropsychological evaluation as part of their clinical workup. The burden of progressive supranuclear palsy‐related tau pathology (neurofibrillary tangles/pretangles, coiled bodies, tufted astrocytes, and threads) was semiquantitatively scored in 20 vulnerable brain regions. Concurrent pathologies potentially associated with cognitive impairment, such as Alzheimer's‐type pathology, were also assessed. To evaluate possible genetic risk factors for cognitive impairment, genetic analysis for APOE and MAPT was performed. Results Ninety patients (74%) had documented cognitive impairment based on neurologic evaluation. In a subgroup with neuropsychological testing (n = 37), executive functioning was the most severely impaired cognitive domain. A global cognitive impairment index (Spearman's rho, −0.49; P = 0.005) and executive functioning were negatively correlated with total tau burden (Spearman's rho, −0.51; P = 0.003), but not correlated with the Alzheimer's‐type pathology. APOE ɛ4 carriers had more severe amyloid pathology, but total tau burden and a global cognitive impairment index did not differ from APOE ɛ4 noncarriers. Conclusion Cognitive impairment in progressive supranuclear palsy, most notably executive dysfunction, is associated with severity of progressive supranuclear palsy‐related tau pathology. © 2017 International Parkinson and Movement Disorder Society
ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer
Reese, Jordan , Bruinsma, Elizabeth S. , Negron, Vivian , Hawse, John R. , Reese, Jordan M, Monroe, David G. , Ingle, James N. , Suman, Vera J. , Goetz, Matthew P.

Oncotarget | October 29, 2017 | Volume: 8 | Issue: 57 | Pages: 96506-96521

10.18632/oncotarget.21787 | PMID 29228549 Get It

Large-vessel giant cell arteritis: diagnosis, monitoring and management
Matteson, Eric L. , Warrington, Kenneth J. , Warrington, Kenneth J , Koster, Matthew J.

Rheumatology | October 28, 2017 | Volume: 57 | Issue: suppl_2 | Pages: ii32-ii42

10.1093/rheumatology/kex424 | PMID 29982778 Get It

OPTN p.Met468Arg and ATXN2 intermediate length polyQ extension in families with C9orf72 mediated amyotrophic lateral sclerosis and frontotemporal dementia
Petrucelli, Leonard , Strong, Michael J. , Gendron, Tania F. , Strong, Michael J , Farhan, Sali M K , Hegele, Robert Alexander

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics | October 28, 2017 | Volume: 177 | Issue: 1 | Pages: 75-85

10.1002/ajmg.b.32606 | PMID 29080331 Get It

We have ascertained two families affected with familial amyotrophic lateral sclerosis (ALS) in which they both carry a hexanucleotide repeat expansion in the C9orf72 gene, specifically in individuals who also presented with frontotemporal dementia (FTD) or behavioral variant FTD (bvFTD). While some reports attribute this phenotypic heterogeneity to the C9orf72 expansion alone, we screened for additional genetic variation in known ALS‐FTD genes that may also contribute to or modify the phenotypes. We performed genetic testing consisting of C9orf72 hexanucleotide expansion, ATXN2 polyglutamine (polyQ) expansion, and targeted next generation sequencing using the ONDRISeq, a gene panel consisting of 80 genes known to be associated with neurodegenerative diseases such as ALS, FTD, Alzheimer's disease, Parkinson's disease, and vascular cognitive impairment. In addition to the C9orf72 expansion, we observed an ATXN2 polyQ intermediate length expansion, and OPTN p.Met468Arg in patients who exhibited ALS and FTD or bvFTD. We conclude that the C9orf72 expansion likely explains much of the ALS‐FTD phenotype; however, inheritance of these additional variants likely modifies the disease course and may provide further evidence for biologically relevant oligogenic inheritance in ALS.
MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia
Abeykoon, Jithma P. , Paludo, Jonas , King, Rebecca L. , Ansell, Stephen M. , LaPlant, Betsy, Halvorson, Alese E. , Gonsalves, Wilson I. , Dingli, David , Lacy, Martha Q. , He, Rong , Kourelis, Taxiarchis , Reeder, Craig B. , Novak, Anne J. , McPhail, Ellen D. , Viswanatha, David S., Witzig, Thomas E. , Go, Ronald S. , Leung, Nelson , Lin, Yi , Thompson, Carrie A. , Hayman, Suzanne R. , Kyle, Robert A. , Kumar, Shaji , Kapoor, Prashant , LaPlant, Betsy R, Gonsalves, Wilson , Witzig, T.E. , Go, Ronald S , Buadi, Francis K. , Leung, Nelson , McPhail, Ellen Darcy , Paludo, Jonas , Dingli, David , Lin, Yi , Gertz, Morie A. , Fang, Hong , Rajkumar, S. Vincent , Habermann, Thomas M. , Dispenzieri, Angela

American Journal of Hematology | October 28, 2017 | Volume: 93 | Issue: 2 | Pages: 187-194

10.1002/ajh.24955 | PMID 29080258 Get It

AbstractWaldenström macroglobulinemia (WM) is an immunoglobulin M‐associated lymphoma, with majority of cases demonstrating MYD88 locus alteration, most commonly, MYD88L265P. Owing to low prevalence of the wild‐type (WT) MYD88 genotype in WM, clinically relevant data in this patient population are sparse, with one study showing nearly a 10‐fold increased risk of mortality in this subgroup compared to patients with MYD88L265P mutation. We studied a large cohort of patients with MYD88L265P and MYD88WT WM, evaluated at Mayo Clinic, Rochester, between 1995 and 2016, to specifically assess the impact of these genotypes on clinical course. Of 557 patients, MYD88L265P mutation status, as determined by allele‐specific polymerase chain reaction, was known in 219, and 174 (79%) of those exhibited MYD88L265P, 157 of 174 patients had active disease. Of 45 (21%) patients with MYD88WT genotype, 44 had active disease. The estimated median follow‐up was 7.0 years; median overall survival was 10.2 years (95% CI: 8.4‐16.5) for MYD88L265P versus 13.9 years (95% CI: 6.4‐29.3) for the MYD88WT (P = 0.86). The time‐to‐next therapy from frontline treatment and the presenting features were similar in the two patient populations. For patients with smoldering WM at diagnosis, the median time‐to‐progression to active disease was 2.8 years (95% CI: 2.2‐3.8) in the MYD88L265P cohort and 1.9 years (95% CI: 0.7‐3.1) in the MYD88WT cohort (P = 0.21). The frequency of transformation to high‐grade lymphoma, or the development of therapy‐elated myelodysplastic syndrome was higher in the MYD88WT cohort (16% versus 4% in the MYD88L265P, P = 0.009). In conclusion, MYD88L265P mutation does not appear to be a determinant of outcome, and its presence may not be a disease‐defining feature in WM. Our findings warrant external validation, preferably through prospective studies.